Impact of antiepileptic drugs on genesis of psychosis

Epilepsy and Behavior

Volumn 23, Issue 4, 2012, Pages 462-465

  Noguchi, Takahiro ^a   Fukatsu, Naofumi ^a   Kato, Hiroko ^a   Oshima, Tomohiro ^a   Kanemoto, Kousuke ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiepileptic drugs; Partial epilepsy; Phenytoin; Psychosis; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; INTELLIGENCE; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PATHOGENESIS; PREDICTIVE VALUE; PSYCHOSIS; RISK FACTOR;

ADOLESCENT; ADULT; ANTICONVULSANTS; EPILEPSY, COMPLEX PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; ISOXAZOLES; MALE; MIDDLE AGED; PHENYTOIN; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84859162602     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.01.012     Document Type: Article

References (40)

1. Trimble M.R. The psychosis of epilepsy 1991, Raven Press, New York.
2. Matsuura M., Oana Y., Kato M., et al. A multi-center study on the prevalence of psychiatric disorders among new referrals for epilepsy in Japan. Epilepsia 2003, 44(1):l07-l14.
3. Qin P., Huilan X., Laursen T.M., Vestergaard M., Mortensen P.B. Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study. BMJ 2005, 331(7507):23.
4. Gibbs F.A. Ictal and non-ictal psychiatric disorders in temporal lobe epilepsy. J Nerv Ment Dis 1951, 113:522-528.
5. Slater E., Beard A.W., Glithero E. The schizophrenia-like psychoses of epilepsy. Br J Psychiatry 1963, 109:95-150.
6. Perez M.M., Trimble M.R. Epileptic psychosis-diagnostic comparison with process schizophrenia. Br J Psychiatry 1980, 137:245-249.
7. Kanemoto K., Tsuji T., Kawasaki Jun Reexamination of interictal psychoses based on DSM IV psychosis and classification and international epilepsy classification. Epilepsia 2001, 42(1):98-103.
8. Schmitz B., Wolf P. Psychosis in epilepsy: frequency and risk factors. J Epilepsy 1995, 8:295-305.
9. Devinsky O., Abramson H., Alper K., et al. Postictal psychosis: a case control series of 20 patients and 150 controls. Epilepsy Res 1995, 20(3):247-253.
10. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998, 155:325-336.
11. Adachi N., Matsuura M., Okubo Y., et al. Predictive variables of interictal psychosis in epilepsy. Neurology 2000, 55(9):1310-1314.
12. Alper K., Kuzniecky R., Carlson C., et al. Postical psychosis in partial epilepsy: a case-control study. Ann Neurol 2008, 63:602-610.
13. Lennox W. Brain injury, drugs, and environment as causes of mental decay in epilepsy. Am J Psychiatry 1942, 99:174-180.
14. Trimble M.R., Reynolds E.H. Anticonvulsant drugs and mental symptoms. a review. Psychol Med 1976, 6:168-178.
15. Matsuura M. Epileptic psychoses and anticonvulsant drug treatment. Neurol Neurosurg Psychiatry 1999, 67:231-233.
16. Besag F.M. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 2004, 3:1-8.
17. World Health Organization The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines 1992, World Health Organization, Geneva, Switzerland.
18. SPSS Inc SPSS 19.0, base system and regression models 1999, SPSS, Chicago.
19. Gillberg C., Persson E., Grufman M., Themner U. Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects. Br J Psychiatry 1986, 149:68-74.
20. Devinsky O. What do you do when they grow up? Approaches to seizures in developmentally delayed adults. Epilepsia 2002, 43(Suppl. 3):71-79.
21. Hassiotis A., Ukoumunne O., Tyrer P., et al. Prevalence and characteristics of patients with severe mental illness and borderline intellectual functioning: report from the UK700 randomised controlled trial of case management. Br J Psychiatry 1999, 175:135-140.
22. Adachi N., Matuura M., Hara T., et al. Psychoses and epilepsy: are interictal and postictal psychoses distinct clinical entities?. Epilepsia 2002, 43(12):1574-1582.
23. Kawasaki J., Sengoku A., Kanemoto K., Kawai I., Inoue Y. The occurrence of acute paranoid-hallucinatory state in epilepsy; in association with antiepileptic drugs. Seishin Igaku 1991, 33:595-600. (in Japanese).
24. Matsuura M., Senzaki A., Okubo Y., Matsushima E., Kojima T., Toru M. Eight epileptic patients showing delusional-hallucinatory state during zonisamide administration. Seishin Igaku 1993, 35:413-419. (in Japanese).
25. Michael C.T., Starr J.L. Psychosis following initiation of zonisamide. Am J Psychiatry 2007, 164:682.
26. Abdoh M., Mersfelder T.L., Melgar T.A. Psychosis induced by zonisamide: a case report and review of the literature. Am J Ther 2011, Oct 17. [Electronic publication ahead of print].
27. Matsuura M., Trimble M.R. Zonisamide and psychosis. J Epilepsy 1997, 10:52-54.
28. Miyamoto T., Kohsaka M., Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000, 9:65-70.
29. White J.R., Walczak T.S., Marino S.E., Beniak T.E., Leppik I.E., Birnbaum A.K. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010, 10:75(6):513-518.
30. Weintraub D., Buchsbaum R., Resor S., Hirsch L.J. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007, 10(1):105-110.
31. Okada M., Kaneko S., Hirano T., et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995, 22:193-205.
32. Murata M., Hasegawa K., Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007, 68:45-50.
33. McDanal C.E., Bolaman W.M. Delayed idiosyncratic psychosis with diphenylhydantoin. JAMA 1975, 231:1063.
34. Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999, 40(10):65-70.
35. Gatzonis S.D., Angelopoulos E., Sarigiannis P., Mantouvalos V., Ploumbidis D., Siafakas A. Acute psychosis due to treatment with phenytoin in a nonepileptic patient. Epilepsy Behav 2003, 4(6):771-772.
36. Logan W.J., Freeman J.M. Pseudodegenerative disease due to diphenylhydantoin intoxication. Arch Neurol 1969, 21:631-637.
37. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure Jun 1998, 7(3):207-211.
38. Mula M., Trimble M.R., Lhatoo S.D., Sander J.W. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003, 44:659-663.
39. Mula M., Trimble M.R., Yuen A., Liu R.S., Sander J.W. Psychiatric adverse events during levetiracetam therapy. Neurology 2003, 61:704-706.
40. Cramer J.A., De Rue K., Devinsky O., Edrich P., Trimble M.R. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003, 4:124-132.